Cablivi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Cablivi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to factors such as increased regulatory approvals, a stronger focus on healthcare and biotech infrastructure development, enhanced safety monitoring, the rise of personalized and targeted therapies, and the growing use of nanobodies.

The expected growth during the forecast period can be attributed to rising investments in research and development, expanding applications in diagnostics, the growing prevalence of cancer, increased awareness of rare diseases, and higher investment in rare disease research. Key trends during the forecast period include advancements in cancer biomarker research, progress in biotechnology and genetic engineering, the integration of AI and big data, the adoption of advanced manufacturing technologies, and the integration with diagnostic technologies.

The growing prevalence of thrombotic thrombocytopenic purpura (TTP) is expected to drive the growth of the cablivi market in the future. Thrombotic Thrombocytopenic Purpura (TTP) is a rare and life-threatening blood disorder characterized by the formation of small blood clots in blood vessels throughout the body. The increasing incidence of TTP is largely due to advances in diagnostic methods, greater awareness among healthcare providers, improved genetic testing, and better recognition of its symptoms. Cablivi (caplacizumab) is effective for treating TTP as it specifically targets and inhibits the von Willebrand factor (vWF), preventing the formation of microclots that contribute to the symptoms of TTP. For example, in July 2023, the National Library of Medicine reported that TTP has an incidence of 3-11 cases per million people and a prevalence of 10 cases per million, with the highest occurrence typically in individuals in their fifth decade of life in the USA. If left untreated, the mortality rate can reach 90%, but proper treatment reduces it to 10%-15%. As a result, the rising prevalence of TTP is driving the growth of the cablivi market.

The increasing number of clinical trials is expected to further accelerate the growth of the cablivi market. Clinical trials are research studies involving human participants to assess the safety, efficacy, and effectiveness of medical treatments, drugs, or devices. The number of clinical trials is rising due to advancements in medical research and technology, the growing incidence of chronic and complex diseases, and the aging global population, which demands new treatments. Cablivi benefits from clinical trials by providing solid evidence of its safety and efficacy in treating TTP, which has contributed to its regulatory approval and widespread use in clinical settings. For example, in February 2024, ClinicalTrials.gov reported that the number of clinical trials increased from 4,024 in 2022 to 5,063 in 2023. Thus, the rise in clinical trials is propelling the growth of the cablivi market.

The growing trend of personalized medicine is also expected to boost the cablivi market. Personalized medicine involves tailoring healthcare treatments to individual patient characteristics, including their genetic makeup, environment, and lifestyle, to achieve the most effective and precise outcomes. The demand for personalized medicine is increasing due to advancements in genomic technologies, a better understanding of molecular biology, more available precision diagnostic tools, and a higher demand for targeted therapies that improve patient outcomes while minimizing side effects. Cablivi benefits from personalized medicine as it provides targeted treatment for patients with acquired thrombotic thrombocytopenic purpura (aTTP), optimizing its efficacy and minimizing side effects based on each patient's specific characteristics and disease profile. For instance, in 2023, the Personalized Medicine Coalition reported that the FDA approved personalized medicines for 34% of new drugs in 2022, compared to 25% during the previous eight years. Therefore, the rise of personalized medicine is driving the growth of the cablivi market.

The key company operating in the cablivi market is Sanofi S.A.

North Amercia was the largest region in the cablivi market in 2024. The regions covered in cablivi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cablivi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cablivi, also known as caplacizumab-yhdp, is a recombinant humanized nanobody designed to inhibit the von Willebrand factor (vWF). It is primarily used in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a rare and potentially fatal blood disorder characterized by the formation of excessive blood clots in small blood vessels.

The key clinical indications for the cablivi market are acquired thrombotic thrombocytopenic purpura (aTTP) and congenital thrombotic thrombocytopenic purpura (cTTP). Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare and severe condition in which blood clots form in small blood vessels, leading to a reduction in platelet count. Cablivi is distributed through various channels, including direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies. It is used by a range of end users, including hospitals, clinics, ambulatory care facilities, and home care settings.

The cablivi market research report is one of a series of new reports that provides cablivi market statistics, including cablivi industry global market size, regional shares, competitors with a cablivi market share, detailed cablivi market segments, market trends and opportunities, and any further data you may need to thrive in the cablivi industry. This cablivi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cablivi market consists of sales of cablivi injection, and cablivi treatment kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.